



OPEN

Propofol abolishes torsade de pointes in different models of acquired long QT syndrome

Christian Ellermann^{1,2✉}, Hilke Könnemann¹, Julian Wolfes¹, Benjamin Rath¹, Felix K. Wegner¹, Kevin Willy¹, Dirk G. Decherer¹, Florian Reinke¹, Lars Eckardt¹ & Gerrit Frommeyer¹

There is conflicting evidence regarding the impact of propofol on cardiac repolarization and the risk of torsade de pointes (TdP). The purpose of this study was to elucidate the risk of propofol-induced TdP and to investigate the impact of propofol in drug-induced long QT syndrome. 35 rabbit hearts were perfused employing a Langendorff-setup. 10 hearts were perfused with increasing concentrations of propofol (50, 75, 100 μM). Propofol abbreviated action potential duration (APD_{90}) in a concentration-dependent manner without altering spatial dispersion of repolarization (SDR). Consequently, no proarrhythmic effects of propofol were observed. In 12 further hearts, erythromycin was employed to induce prolongation of cardiac repolarization. Erythromycin led to an amplification of SDR and triggered 36 episodes of TdP. Additional infusion of propofol abbreviated repolarization and reduced SDR. No episodes of TdP were observed with propofol. Similarly, ondansetron prolonged cardiac repolarization in another 13 hearts. SDR was increased and 36 episodes of TdP occurred. With additional propofol infusion, repolarization was abbreviated, SDR reduced and triggered activity abolished. In this experimental whole-heart study, propofol abbreviated repolarization without triggering TdP. On the contrary, propofol reversed prolongation of repolarization caused by erythromycin or ondansetron, reduced SDR and thereby eliminated drug-induced TdP.

Up to 22% of patients treated on intensive care units experience ventricular arrhythmias and have a higher mortality compared to patients without heart rhythm disturbances¹. Many risk factors have been identified over the past decades and include individual characteristics of each patient but also external factors such as use of pharmacological agents that impair repolarization reserve. Since propofol is commonly used in anaesthesia and intensive care medicine, the impact of propofol alone or in combination with other drugs that influence cardiac electrophysiology is of great interest. As a consequence, some studies have already investigated the electrophysiological effects of propofol in vivo and vitro:

Intravenous application of propofol has direct impact on several ion currents including I_{Na} , some potassium channels (I_{Ks} , I_{Kto} , I_{K1}), and I_{CaL} ²⁻⁵. However, previous clinical and experimental studies report conflicting data regarding its impact on ventricular repolarization and potential proarrhythmic effects. Higashijima et al. described a significant abbreviation of QTc interval during anaesthetic induction mediated by propofol⁶. In contrast, a recent study demonstrated an increase in ventricular repolarization duration calculated by Fridericia-corrected QT interval with propofol⁷. Additionally, T_{peak} to T_{end} interval ($T_{\text{peak}}-T_{\text{end}}$) was significantly amplified in the presence of propofol in this study. An increased $T_{\text{peak}}-T_{\text{end}}$ interval is a surrogate for an amplified transmural dispersion of repolarization which in turn represents a major risk factor for drug-induced arrhythmias⁸. In contrast to this study, no significant changes of QTc or $T_{\text{peak}}-T_{\text{end}}$ have been reported during propofol infusion in children⁹.

Some other experimental studies have investigated effects of propofol in different models of long QT syndrome (LQTS): In healthy and transgenic LQT2 and LQT3 rabbits, propofol administration resulted in an increase of QT index resulting in arrhythmia-related death in two LQT2 rabbits⁵. In another study employing a model of (drug-induced) LQTS, propofol reduced the action potential duration increase mediated by erythromycin¹⁰.

¹Department of Cardiology II (Electrophysiology), University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany. ²Klinik für Kardiologie II – Rhythmologie, Universitätsklinikum Münster, Albert-Schweitzer Campus 1, 48149 Münster, Germany. ✉email: christian.ellermann@ukmuenster.de

In conclusion, existing studies report conflicting data concerning propofol-induced changes in repolarization duration and heterogeneity and provocation of arrhythmias. Therefore, the purpose of the present study was to elucidate propofol's impact in a sensitive model of repolarization disorders. Previous experimental studies have solely investigated the effect of propofol infusion on ventricular repolarization duration and other ECG markers (e.g. $T_{\text{peak}}-T_{\text{end}}$) but did not investigate other proarrhythmic mechanisms such as dispersion of repolarization or action potential shape. Thus, this study aimed at elucidating further potential mechanisms in arrhythmia initiation induced by propofol.

Methods

All experimental protocols were approved by the local animal care committee (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, Germany) and were carried out in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 852-3, revised 1996). Since hearts served as their own control, no randomization of the hearts was performed.

The experimental setting of the antegradely-perfused Langendorff-heart has been described earlier extensively¹¹. In short, 35 hearts of female New Zealand white rabbits were explanted and mounted to a Langendorff apparatus. Spontaneously beating hearts were perfused by a warmed, oxygenated (95% O₂, 5% CO₂) modified Krebs–Henseleit buffer (NaCl 118 mM, NaHCO₃ 24.88 mM, D-glucose 5.55 mM, KCl 4.70 mM, Na-pyruvate 2 mM, CaCl₂ 1.80 mM, KH₂PO₄ 1.18 mM, MgSO₄ 0.83 mM) at a constant flow (52 mL/min) with a pressure around 90 mmHg. Monophasic action potentials (MAP) were acquired by eight specifically designed MAP catheters that were placed endo- and epicardially. Hearts were immersed in a warmed tissue bath, thereby enabling recording of a volume-conducted 12-lead ECG. Spontaneously beating hearts were mechanically AV node-ablated using surgical tweezers in order to perform the following stimulation protocol.

Hearts were stimulated at seven different cycle lengths (90–300 ms), thus obtaining cycle-lengths dependent QT interval and action potential duration (APD₉₀). APD₉₀ was measured between the fastest upstroke and 90% of repolarization. Premature extra-stimuli (S₂ and S₃) were delivered to the hearts in order to assess ventricular vulnerability and to determine effective refractory periods (ERP) at different basic cycle-lengths (900–300 ms, see Fig. 1). In case sustained ventricular arrhythmias occurred after short-coupled extra-stimuli, hearts were defibrillated, and the pacing protocol was halted for 5 min to assure recovery of the hearts. Post-repolarization refractoriness (PRR) was calculated as the difference between ERP and APD₉₀. Spatial dispersion of repolarization was determined by the difference of maximum and minimum of the APD₉₀ of the eight MAPs. Configuration of action potentials is displayed by the ratio of APD₉₀/APD₅₀^{12,13}.

Hearts were divided into three different groups: In the first group, propofol in ascending concentrations (50, 75, 100 μM) was infused after generating baseline data and the protocol was repeated for each concentration. In this experimental arm, premature extra-stimuli were solely delivered after pacing the hearts at a basic cycle-length of 500 ms in order to abridge the experimental protocol. The second group was perfused with 300 μM erythromycin after generating baseline data. Afterwards, hearts were additionally treated with 75 μM propofol. The last group was infused with 5 μM ondansetron and thereafter 75 μM propofol was added. Before continuing the experimental protocol with a new drug or concentration, hearts were equilibrated for 15 min.

Statistics. Electrograms and action potentials were recorded on a multi-channel recorder and digitalized at a rate of 1 kHz with a 12-bit resolution. Variables are shown as mean ± standard deviation. Statistical analyses were performed using SPSS Statistics for Windows (version 24.0). Drug effects on APD₉₀, QT interval, dispersion of repolarization, action potential configuration (APD₉₀/APD₅₀), ERP and PRR were analysed employing Wilcoxon signed rank test. P values < 0.05 were considered to be statistically significant. Data are expressed as mean ± standard deviation.

Results

Propofol effects on ventricular repolarization and arrhythmia induction. Infusion of propofol abbreviated APD₉₀ in a concentration-dependent manner (baseline: 158 ± 25 ms; 50 μM: 142 ± 21 ms, p < 0.01 compared to baseline; 75 μM: 129 ± 19 ms, p < 0.01 compared to baseline; 100 μM: 129 ± 23 ms, p < 0.01 compared to baseline; Fig. 2) while QT interval remained relatively stable at the lowest propofol concentration and was slightly abbreviated under the influence of 75 and 100 μM propofol (baseline: 242 ± 30 ms; 50 μM: 243 ± 35 ms, p = ns; 75 μM: 241 ± 32 ms, p = 0.07; 100 μM: 239 ± 27 ms, p < 0.01; each p compared to baseline).

ERP were increased after propofol treatment in a concentration-dependent manner (baseline: 196 ± 65 ms; 50 μM: 196 ± 44 ms, p = ns; 75 μM: 201 ± 33 ms, p = ns; 100 μM: 222 ± 44 ms, p = ns), resulting in a significant amplification of PRR (baseline: 38 ± 43 ms; 50 μM: 58 ± 43 ms, p = ns; 75 μM: 76 ± 27 ms, p < 0.02; 100 μM: 86 ± 51 ms, p = ns).

Spatial dispersion of repolarization was not significantly altered at lowest or highest propofol concentration but was decreased with 75 μM propofol (baseline: 43 ± 15 ms; 50 μM: 45 ± 14 ms, p = ns; 75 μM: 36 ± 13 ms, p < 0.05; 100 μM: 39 ± 15 ms, p = ns).

The action potential shape which can be expressed by the ratio of APD₉₀/APD₅₀ was not significantly changed in the presence of 50 or 75 μM propofol (baseline: 1.48 ± 0.13, 50 μM: 1.44 ± 0.11, p = ns; 75 μM: 1.47 ± 0.11, p = ns). However, with the highest concentration tested (100 μM), a further rectangulation of action potential shape could be observed (1.42 ± 0.14, p = 0.01).

3 episodes of ventricular tachycardia or fibrillation were inducible by programmed ventricular stimulation (S₂ and S₃) under baseline conditions. No episodes occurred with 50 μM propofol (p = ns) while 2 episodes of VT/VF were inducible under the influence of 75 μM propofol (p = ns). With the highest propofol concentration (100 μM) 6 episodes of VT/VF were inducible (p = ns).




Figure 1. Determination of effective refractory periods (MAP = monophasic action potential).

Erythromycin. Treatment with 300 μM erythromycin prolonged QT interval from 246 ± 27 ms to 275 ± 30 ms ($p < 0.01$; Fig. 3) while APD_{90} was just slightly increased from 168 ± 18 ms to 171 ± 28 ms ($p = \text{ns}$). Propofol reversed these effects and abbreviated QT interval to 267 ± 18 ms ($p < 0.01$) and APD_{90} to 158 ± 23 ms ($p < 0.01$). Spatial dispersion of repolarization was significantly amplified in the presence of erythromycin (baseline: 40 ± 16 ms; erythromycin: 48 ± 18 ms, $p < 0.01$) and reduced by the additional treatment with propofol to 42 ± 12 ms ($p = 0.01$ compared to erythromycin).

There was a trend towards an increase of $\text{APD}_{90}/\text{APD}_{50}$ after infusion of erythromycin from 1.49 ± 0.12 to 1.52 ± 0.19 ($p = 0.13$), representing a triangulation of action potential shape. With propofol, a non-significant decrease of the $\text{APD}_{90}/\text{APD}_{50}$ ratio was observed (1.48 ± 0.10 , $p = 0.21$).

No torsade de pointes occurred under baseline conditions. However, 36 episodes of torsade de pointes spontaneously occurred after treatment with erythromycin ($p < 0.05$ compared to baseline) and were completely eliminated in the presence of propofol (0 episodes, $p < 0.05$).




Figure 2. (a) Cycle-length dependent APD₉₀ under baseline conditions (filled rhombus) and after treatment with 50 μM (filled square), 75 μM (filled triangle) or 100 μM (filled circle) propofol. (b) Impact of propofol on effective refractory periods (ERP). (c) Concentration-dependent effect of propofol on post-repolarization refractoriness ([#]*p* < 0.05 compared to baseline conditions). (d) Box plots of the ratio of action potential duration at 90% of repolarization (APD₉₀) and action potential duration at 50% of repolarization (APD₅₀). A decrease in APD₉₀/APD₅₀ represents a rectangularization of action potential. (e) Influence of propofol treatment on repolarization heterogeneity as indicated by spatial dispersion of repolarization ([#]*p* < 0.05 compared to baseline conditions). (f) Occurrence of ventricular fibrillation (VF) tachycardia (VT) induced by programmed ventricular fibrillation.

Ondansetron. With ondansetron, an increase of QT interval from 252 ± 46 ms to 309 ± 68 ms (*p* = ns; Fig. 4) and of APD₉₀ from 162 ± 28 to 174 ± 32 ms (*p* < 0.01) was observed. Additional infusion of propofol abbreviated QT interval (to 289 ± 61 ms, *p* = ns) as well as APD₉₀ (to 150 ± 23 ms, *p* < 0.01). Spatial dispersion of repolarization was amplified after ondansetron infusion (from 40 ± 20 ms to 59 ± 24 ms, *p* < 0.01) and substantially reduced under the additional influence of propofol (37 ± 16 ms, *p* < 0.01).

The APD₉₀/APD₅₀ ratio was significantly increased in the presence of ondansetron from 1.53 ± 0.18 to 1.56 ± 0.15 (*p* < 0.05). Propofol did not significantly alter the APD₉₀/APD₅₀ ratio (1.53 ± 0.19 ; *p* = ns).

No episodes of torsade de pointes occurred in the spontaneously beating, AV-blocked hearts under baseline conditions. With ondansetron, 36 episodes of torsade de pointes were observed (*p* < 0.02, Fig. 5). Again, propofol treatment eliminated torsade de pointes in each heart (0 episodes, *p* < 0.02).

Discussion

To our best knowledge, this is the first experimental whole-heart study investigating propofol's effects on cardiac electrophysiology in different models of acquired long QT syndrome. This study demonstrates that sole propofol infusion slightly abbreviates ventricular repolarization without triggering torsade de pointes. Furthermore, administration of propofol on top of proarrhythmic agents such as erythromycin or ondansetron reduces repolarization and spatial dispersion of repolarization and thereby eliminates torsade de pointes.

Impact of propofol on cardiac electrophysiology. In the present study, propofol induced a significant abbreviation of cardiac repolarization as indicated by APD₉₀ and QT interval. This is in line with the majority of former clinical studies investigating repolarization duration under the influence of propofol¹⁴. Previous data




Figure 3. (a,b) Cycle-length dependent APD₉₀ and QT interval under baseline conditions (filled rhombus), after treatment with 300 μM erythromycin (filled square) and after additional infusion of 75 μM propofol (filled triangle). (c) Box plots of the ratio of APD₉₀ to APD₅₀. (d) Impact of erythromycin and propofol on spatial dispersion of repolarization (*p < 0.05 compared to baseline conditions; *p < 0.05 compared to sole erythromycin infusion). (e) Occurrence of torsade de pointes under baseline conditions, with erythromycin and with the combination of erythromycin and propofol (*p < 0.05 compared to baseline conditions; *p < 0.05 compared to sole erythromycin treatment).

concerning propofol's influence on $T_{\text{peak}}-T_{\text{end}}$ is equivocal. While a recent clinical study showed a prolonged $T_{\text{peak}}-T_{\text{end}}$ interval with propofol⁷, no changes were observed in another trial with a paediatric study cohort⁹. $T_{\text{peak}}-T_{\text{end}}$ interval has been proposed as a surrogate for transmural dispersion of cardiac repolarization¹⁵. In contrast to the QT interval that mediocly predicts occurrence of torsade de pointes, an increased transmural dispersion of repolarization is a good indicator for drug-induced arrhythmias^{8,13}. This study clearly indicates a stable dispersion of repolarization during propofol-treatment even at supratherapeutic concentrations. A stable dispersion of repolarization (even in the presence of a prolonged cardiac repolarization) is linked to a safe electrophysiological profile of several antiarrhythmic drugs¹⁶.

Furthermore, the shape of action potential duration was transformed by the highest concentration of propofol to a more rectangular shape as indicated by a decrease in APD₉₀/APD₅₀. A rectangulation of action potential reduces the risk of arrhythmias and is mediated by an acceleration of phase 3 repolarization which reduces the time in the window voltage for calcium channel reactivation and subsequent triggered activity¹². Thus, no arrhythmias were observed in bradycardic hearts even with the highest concentration of propofol used. As a consequence, this study highlights a good safety profile of propofol. With propofol, post-repolarization refractoriness was significantly lengthened. Prolongation of PRR protects the myocardium against premature beats, is therefore antiarrhythmic^{11,17} and a common pharmacological property of class I antiarrhythmic drugs. Consequently, ventricular vulnerability as tested by programmed ventricular stimulation was not increased with propofol.

In this study, supratherapeutic concentrations of propofol have been employed to determine adverse drug effects. Mean propofol concentration during anesthesia induction is 11.7 (± 5.0) μg/mL which equals approximately 65.6 μM¹⁸. However, since genetic polymorphisms in hepatic metabolizing enzymes (e.g. CYP2C9) may further increase propofol concentrations during anaesthesia¹⁸, higher plasma concentrations might be achieved. Therefore, concentrations of up to 100 μM have been employed in this study.




Figure 4. (a,b) Cycle-length dependent APD₉₀ and QT interval under baseline conditions (filled rhombus), after treatment with 5 μM ondansetron (filled square) and after additional infusion of 75 μM propofol (filled triangle). (c) Box plots of the ratio of APD₉₀ to APD₅₀ (*p < 0.05 compared to baseline conditions) (d) Influence of ondansetron and propofol on spatial dispersion of repolarization (#p < 0.05 compared to baseline conditions; *p < 0.05 compared to sole ondansetron administration). (e) Occurrence of torsade de pointes under baseline conditions, with ondansetron and with the combination of ondansetron and propofol (*p < 0.05 compared to baseline conditions; *p < 0.05 compared to sole ondansetron treatment).

Models of acquired long QT syndrome. With erythromycin, a marked prolongation of repolarization duration, an amplification of spatial dispersion of repolarization and a trend towards a triangulation of action potential shape were observed. This is in line with previous studies in which the I_{Kr} inhibitor erythromycin was employed to simulate LQT2 syndrome¹¹. Similar results have been achieved for ondansetron which also inhibits hERG (human Ether-a-go-go Related Gene) potassium channels¹⁹. Accordingly, ondansetron augmented repolarization duration and amplified spatial dispersion of repolarization²⁰.

Erythromycin and ondansetron changed the shape of the action potential to a more triangular shape which can be explained by an inhibition of I_{Kr} (Fig. 6). This leads to a slowing of phase 3 repolarization which in turn prolongs the time frame in which early afterdepolarizations and subsequent torsade de pointes can be generated¹². Consequently, early afterdepolarizations and torsade de pointes were observed with both drugs.

In contrast, infusion of propofol reversed the changes induced by erythromycin or ondansetron. To be more precise, propofol abbreviated repolarization and reduced spatial dispersion of repolarization in both groups. Previous studies demonstrated that a decrease of spatial dispersion of repolarization is a crucial antiarrhythmic mechanism in acquired long QT syndrome^{11,17}. Recently, Bossu and colleagues²¹ elegantly demonstrated that reduction of spatial dispersion of repolarization induced by the I_{Na,L} inhibitor GS967 predominantly inhibits perpetuation of torsade de pointes in the chronic atrioventricular block dog. It is noteworthy that early afterdepolarization which are regarded as initiating mechanism were just slightly suppressed. Consequently, the prevention of perpetuation instead of prevention of the initiation of the arrhythmia can be regarded as the antiarrhythmic mechanism of GS967 in this study²¹. Similarly, the crucial antiarrhythmic action of propofol in this study might not be inhibition of triggered activity but rather prevention of perpetuation of torsade de pointes tachycardia.

There was a non-significant trend towards a rectangular action potential shape with additional propofol treatment. As a consequence, triggered activity (early afterdepolarizations or torsade de pointes) occurred neither



Figure 5. (a) Representative example of early afterdepolarizations induced by erythromycin (MAP = monophasic action potential). (b) Spontaneously occurring polymorphic ventricular tachycardia resembling torsade de pointes after ondansetron treatment.

in the erythromycin nor in the ondansetron group after additional propofol treatment. These results are in line with a previous study in which propofol reversed the prolongation of repolarization induced by erythromycin. However, no further mechanistic investigations were performed, and no arrhythmias were recorded due to the experimental setup¹⁰. These findings were confirmed in a clinical setting in which propofol reversed QT interval prolongation induced by sevoflurane²².

Surprisingly, in transgenic LQT2 rabbits, propofol prolonged repolarization and subsequently triggered torsade de pointes⁵. Even though above-mentioned studies indicated different effects of propofol in LQTS-linked arrhythmias, one would actually expect similar results since inhibition of I_{Kr} , either by erythromycin or ondansetron is likely to result in similar electrophysiologic effects as observed in LQT2.

Of note, the electrophysiologic effects of propofol in acquired LQTS observed in this study are comparable to those obtained for the sodium current inhibitor mexiletine¹⁷.

Limitations

The present study was conducted in isolated rabbit hearts. Therefore, a direct extrapolation to humans is not possible. However, previous studies indicate that the rabbit heart is a reasonable model for studying cardiac ion channel function and especially for investigating cardiac repolarization disorders²³. Furthermore, the rabbit heart is particularly suitable for studying complex ventricular arrhythmias like ventricular fibrillation due to its effective size, which relates the size of the heart to the wavelength of the arrhythmia²⁴. Following this concept as proposed by Panfilov²⁴, the effective size of the rabbit heart is similar to the human heart leading to a similar arrhythmia pattern in both species.

However, this model does not allow precise statements concerning direct effects on ion channels. Reduction of repolarization duration induced by propofol can probably be explained by the predominant inhibition of sodium and calcium channels that overrides the effects of potassium channel block. Accordingly, distinct effects of propofol on different human cardiac channels have been described and this multi-channel inhibition most likely explains the results observed in this study: To be more precise, previous patch clamp studies reported that propofol inhibits human L-type calcium currents²⁵, human sodium³ as well as human potassium channels²⁶.




Figure 6. Illustrative example of action potential and ECG tracings under baseline conditions (a) and after administration of erythromycin (b) in spontaneously beating bradycardic hearts under hypokalemic conditions. With erythromycin, action potentials are substantially prolonged and triangulated. Of note, spatial dispersion of repolarization (as determined by the duration differences between MAP 5 and MAP 3 in (b)) is amplified. (MAP = monophasic action potential).

Conclusion

The present study demonstrates a safe electrophysiologic profile of propofol even at high concentrations. Propofol abbreviated cardiac repolarization and did not bear the risk of proarrhythmia. Quite the contrary, propofol abbreviated repolarization duration in different models of acquired long QT syndrome, reduced spatial dispersion of repolarization and thereby eliminated drug-induced torsade de pointes. As a consequence, propofol might even be beneficial in drug-induced QT prolongation by reducing the risk of torsade de pointes.

Data availability

The datasets generated during and analysed during the current study are available from the corresponding author on reasonable request.

Received: 24 March 2020; Accepted: 7 July 2020

Published online: 22 July 2020

References

1. Artucio, H. & Pereira, M. Cardiac arrhythmias in critically ill patients: Epidemiologic study. *Crit. Care Med.* **18**, 1383–1388 (1990).
2. Yang, C.-Y., Wong, C.-S., Yu, C.-C., Luk, H.-N. & Lin, C.-I. Propofol inhibits cardiac L-type calcium current in guinea pig ventricular myocytes. *Anesthesiology* **84**, 626–635 (1996).
3. Stoetzer, C. *et al.* Inhibition of the cardiac Na⁺ channel α -subunit Nav1.5 by propofol and dexmedetomidine. *Naunyn Schmiedeberg Arch. Pharmacol.* **389**, 315–325 (2016).
4. Buljubasic, N. *et al.* Differential effects of etomidate, propofol, and midazolam on calcium and potassium channel currents in canine myocardial cells. *Anesthesiology* **85**, 1092–1099 (1996).
5. Odening, K. E. *et al.* Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization. *Am. J. Physiol. Heart Circ. Physiol.* **295**, H2264–H2272 (2008).
6. Higashijima, U. *et al.* A comparison of the effect on QT interval between thiamylal and propofol during anaesthetic induction. *Anaesthesia* **65**, 679–683 (2010).
7. Wutzler, A. *et al.* Effects of propofol on ventricular repolarization and incidence of malignant arrhythmias in adults. *J. Electrocardiol.* **51**, 170–174 (2018).

8. Antzelevitch, C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. *Heart Rhythm*. **2**, S9–S15 (2005).
9. Hume-Smith, H. V., Sanatani, S., Lim, J., Chau, A. & Whyte, S. D. The effect of propofol concentration on dispersion of myocardial repolarization in children. *Anesth. Analg.* **107**, 806–810 (2008).
10. Morey, T. E. *et al.* Ionic basis of the differential effects of intravenous anesthetics on erythromycin-induced prolongation of ventricular repolarization in the guinea pig heart. *Anesthesiology* **87**, 1172–1181 (1997).
11. Ellermann, C. *et al.* Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes. *Europace* **20**, 1699–1706 (2018).
12. Milberg, P. *et al.* Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. *J. Pharmacol. Exp. Ther.* **303**, 218–225 (2002).
13. Frommeyer, G. & Eckardt, L. Drug-induced proarrhythmia: Risk factors and electrophysiological mechanisms. *Nat. Rev. Cardiol.* **13**, 36 (2016).
14. Staikou, C., Stamelos, M. & Stavroulakis, E. Impact of anaesthetic drugs and adjuvants on ECG markers of torsadogenicity. *Br. J. Anaesth.* **112**, 217–230 (2013).
15. Yan, G.-X. & Antzelevitch, C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. *Circulation* **98**, 1928–1936 (1998).
16. Frommeyer, G. *et al.* Electrophysiological profile of vernakalant in an experimental whole-heart model: The absence of proarrhythmia despite significant effect on myocardial repolarization. *Europace* **16**, 1240–1248 (2014).
17. Frommeyer, G. *et al.* Broad antiarrhythmic effect of mexiletine in different arrhythmia models. *Europace* **20**, 1375–1381 (2017).
18. Khan, M. S. *et al.* Pharmacogenetics, plasma concentrations, clinical signs and EEG during propofol treatment. *Basic Clin. Pharmacol. Toxicol.* **115**, 565–570 (2014).
19. Kuryshv, Y. A., Brown, A. M., Wang, L., Benedict, C. R. & Rampe, D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. *J. Pharmacol. Exp. Ther.* **295**, 614–620 (2000).
20. Frommeyer, G. *et al.* Severe proarrhythmic potential of the antiemetic agents ondansetron and domperidone. *Cardiovasc. Toxicol.* **17**, 451–457 (2017).
21. Bossu, A. *et al.* Selective late sodium current inhibitor GS-458967 suppresses Torsades de Pointes by mostly affecting perpetuation but not initiation of the arrhythmia. *Br. J. Pharmacol.* **175**, 2470–2482 (2018).
22. Terao, Y. *et al.* The effects of intravenous anesthetics on QT interval during anesthetic induction with sevoflurane. *J. Anesth.* **30**, 929–934 (2016).
23. Clauss, S. *et al.* Animal models of arrhythmia: Classic electrophysiology to genetically modified large animals. *Nat. Rev. Cardiol.* **16**, 457–475 (2019).
24. Panfilov, A. V. Is heart size a factor in ventricular fibrillation? Or how close are rabbit and human hearts?. *Heart Rhythm*. **3**, 862–864 (2006).
25. Fassl, J., High, K. M., Stephenson, E. R., Yarotsky, V. & Elmslie, K. S. The intravenous anesthetic propofol inhibits human L-type calcium channels by enhancing voltage-dependent inactivation. *J. Clin. Pharmacol.* **51**, 719–730 (2011).
26. Yang, L., Liu, H., Sun, H.-Y. & Li, G.-R. Intravenous anesthetic propofol inhibits multiple human cardiac potassium channels. *Anesthesiology* **122**, 571–584 (2015).

Acknowledgements

This work was supported by the Hans-and-Gertie Fischer Foundation and by the German Cardiac Society (to G.F.). We acknowledge support from the Open Access Publication Fund of the University of Muenster.

Author contributions

C.E., L.E. and G.F. designed the study. C.E., H.K., P.N., J.W., B.R., F.K.W. and K.W. performed the experiments. C.E., D.G.D. and F.R. analyzed the data. C.E., L.E. and G.F. wrote the paper.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to C.E.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020